Disclosure Of First-Time Adoption [Text Block]

OSE Immunotherapeutics - Filing #831399

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	—	—	22 975 EUR	—	57 282 EUR	—	—	76 643 EUR	—	4 330 EUR	309,000 EUR	408,000 EUR	32 658 EUR	—	—	—	35 890 EUR	65 611 EUR	549,000 EUR	3 705 EUR	220,000 EUR	—	—	—	160,000 EUR	47 890 EUR	21 111 EUR	65 605 EUR	150,000 EUR	3 705 EUR
Comprehensive income	23 089 EUR	0 EUR	—	23 012 EUR	—	0 EUR	77,000 EUR	—	0 EUR	—	—	—	—	0 EUR	0 EUR	17 699 EUR	—	—	—	—	—	17 638 EUR	0 EUR	61,000 EUR	—	—	—	—	—	—
Profit (loss)	23 003 EUR	—	—	23 003 EUR	—	—	—	—	—	—	—	—	—	—	—	17 760 EUR	—	—	—	—	—	17 760 EUR	—	—	—	—	—	—	—	—